eligibility_summary
Includes: CDH17+ histologically confirmed solid tumors after standard therapy failure/intolerance, ≥1 measurable lesion, tumor tissue available, ECOG 0–1, adequate organ function, contraception and consent. Excludes: pregnancy/breastfeeding, active HBV/HCV/HIV/syphilis, unresolved toxicities, prior allogeneic transplant or CDH17 CAR‑T, recent major surgery, CNS mets, serious infection/steroid use, major cardiac/QTc issues, uncontrolled HTN, recent stroke, autoimmune disease/immunodeficiency, bleeding risk, severe allergy, recent live vaccine/other trial, recent malignancy, unsafe conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06937567 tests UCLH801, an autologous CDH17-directed CAR-T cell therapy, in CDH17-positive advanced solid tumors (e.g., colorectal, gastric, pancreatic, biliary, neuroendocrine, ovarian, lung). Type/mechanism: patient T cells are genetically engineered to express a chimeric antigen receptor that binds cadherin‑17 (CDH17), a cell-adhesion molecule overexpressed on many epithelial cancers, CAR engagement triggers CD3ζ/costimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CDH17+ tumor cells. Targets: CDH17 on tumor cells, pathways: CDH17 surface antigen and downstream T-cell activation/cytotoxic effector pathways. Early Phase 1, single-arm 3+3 dose escalation (1.0–6.0×10^6 cells/kg).